Cargando…

Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer

The purpose of this study was to evaluate quality of life (QOL) in prostate cancer patients treated with (125)I brachytherapy (BT), (125)I brachytherapy combined with 3D conformal radiation therapy (BT+3D-CRT), or intensity-modulated radiation therapy (IMRT). We evaluated disease-related QOL in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakai, Yasushi, Tanaka, Nobumichi, Asakawa, Isao, Anai, Satoshi, Miyake, Makito, Hori, Shunta, Morizawa, Yosuke, Tatsumi, Yoshihiro, Hasegawa, Masatoshi, Fujii, Tomomi, Fujimoto, Kiyohide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Regular Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430243/ https://www.ncbi.nlm.nih.gov/pubmed/30576565 http://dx.doi.org/10.1093/jrr/rry101

Ejemplares similares

Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2017)

Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2018)

Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute
por: Miyake, Makito, et al.
Publicado: (2017)

Localized prostate cancer with pelvic arteriovenous malformation treated with low‐dose‐rate brachytherapy after transcatheter embolization: Two case reports
por: Owari, Takuya, et al.
Publicado: (2019)

Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report
por: Hori, Shunta, et al.
Publicado: (2014)

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019)

Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases
por: Miyake, Makito, et al.
Publicado: (2017)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2018)

Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
por: Tanaka, Nobumichi, et al.
Publicado: (2013)

Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy
por: Nakai, Yasushi, et al.
Publicado: (2017)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells
por: Tatsumi, Yoshihiro, et al.
Publicado: (2020)

(125)I Seed Implant Brachytherapy for Painful Bone Metastases After Failure of External Beam Radiation Therapy
por: Feng, Shi, et al.
Publicado: (2015)

A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study
por: Miyake, Makito, et al.
Publicado: (2020)

Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas
por: Morizawa, Yosuke, et al.
Publicado: (2016)

Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume
por: Nakai, Yasushi, et al.
Publicado: (2017)

Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy
por: Morizawa, Yosuke, et al.
Publicado: (2018)

The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions
por: Miyake, Makito, et al.
Publicado: (2019)

Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient’s age and prostate volume
por: Hori, Shunta, et al.
Publicado: (2019)

Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model
por: Hori, Shunta, et al.
Publicado: (2017)

CT-guided (125)I brachytherapy for recurrent ovarian cancer
por: Liu, Ping, et al.
Publicado: (2017)

Treatment planning considerations for (125)I eye plaque brachytherapy
por: Miguel, David, et al.
Publicado: (2019)

Annulus-shaped I-125 plaque brachytherapy for conjunctival melanoma
por: Berkowitz, Sean T., et al.
Publicado: (2022)

Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
por: Jiang, Qin, et al.
Publicado: (2021)

Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model
por: Brun, Thomas, et al.
Publicado: (2018)

The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

CT-guided (125)I brachytherapy for locally recurrent nasopharyngeal carcinoma
por: Yan, Huzheng, et al.
Publicado: (2017)

An in vitro verification of strength estimation for moving an (125)I source during implantation in brachytherapy
por: Tanaka, Kenichi, et al.
Publicado: (2018)

Comparison of clinical efficacy and complications of (125)I seed brachytherapy and stereotactic body radiation therapy for recurrent pulmonary metastases from colorectal carcinoma
por: Li, Jie, et al.
Publicado: (2018)

(103)Pd versus (125)I ophthalmic plaque brachytherapy: preoperative comparative radiation dosimetry for 319 uveal melanomas
por: Finger, Paul T., et al.
Publicado: (2014)

Effect of Prolonged Duration of Transrectal Ultrasound-Guided Biopsy of the Prostate and Pre-Procedure Anxiety on Pain in Patients without Anesthesia
por: Nakai, Yasushi, et al.
Publicado: (2021)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Bioevaluation of (125)I Ocu-Prosta seeds for application in prostate cancer brachytherapy
por: Mukherjee, Archana, et al.
Publicado: (2014)

Re-implantation after insufficient primary 125-i permanent prostate brachytherapy
por: Putora, Paul Martin, et al.
Publicado: (2013)

Risk factors for rectal bleeding associated with I-125 brachytherapy for prostate cancer
por: Harada, Kosaku, et al.
Publicado: (2012)

Palliative treatment of pelvic bone tumors using radioiodine ((125)I) brachytherapy
por: Wang, Chongren, et al.
Publicado: (2016)

Dosimetric parameters of three new solid core I‐125 brachytherapy sources
por: Solberg, Timothy D., et al.
Publicado: (2002)

Evaluation of therapeutic effects of (125)I particles brachytherapy for recurrent bladder cancer
por: Zhou, Yu-Ming, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0bc42rlh8h6ifo2qbbsbv3qjqa